Simplify

Health

Care

ETF

Schedule

of

Investments

March

31,

2024

(Unaudited)

1

Shares

Value

Common

Stocks

–

98.1%

Health

Care

–

91.3%

Abbott

Laboratories

........................................................

8,467

$

962,359‌

AbbVie,

Inc.

..............................................................

19,045

3,468,094‌

Akero

Therapeutics,

Inc.*

...................................................

33,199

838,607‌

Align

Technology,

Inc.*

.....................................................

19,251

6,312,788‌

Avantor

Inc*

..............................................................

109,781

2,807,100‌

Bio-Techne

Corp.

.........................................................

9,152

644,209‌

Boston

Scientific

Corp.*

....................................................

62,458

4,277,748‌

Bristol-Myers

Squibb

Co.

...................................................

530

28,742‌

Cigna

Group

(The)

........................................................

24,287

8,820,796‌

Cooper

Cos.,

Inc.

(The)

.....................................................

62,398

6,330,901‌

Danaher

Corp.

............................................................

1,253

312,899‌

Elevance

Health,

Inc.

......................................................

5,239

2,716,631‌

Eli

Lilly

&

Co.

.............................................................

8,041

6,255,576‌

Embecta

Corp.

...........................................................

1,399

18,565‌

Establishment

Labs

Holdings,

Inc.*

...........................................

25,493

1,297,594‌

Exact

Sciences

Corp*

......................................................

64,027

4,421,705‌

Fulcrum

Therapeutics,

Inc.*

.................................................

211,031

1,992,133‌

HCA

Healthcare

Inc

........................................................

1,415

471,945‌

Henry

Schein,

Inc.*

........................................................

3,520

265,830‌

Humana,

Inc.

.............................................................

210

72,811‌

IDEXX

Laboratories,

Inc.*

...................................................

2,819

1,522,063‌

Insulet

Corp.*

.............................................................

14,979

2,567,401‌

Intuitive

Surgical,

Inc.*

......................................................

32,348

12,909,763‌

Johnson

&

Johnson

........................................................

24,295

3,843,226‌

Leap

Therapeutics,

Inc.*

....................................................

375,976

1,000,096‌

LivaNova

PLC*

...........................................................

8,613

481,811‌

Masimo

Corp.*

...........................................................

9,832

1,443,829‌

Merck

&

Co.,

Inc.

..........................................................

47,663

6,289,133‌

Natera,

Inc.*

.............................................................

12,669

1,158,707‌

Regeneron

Pharmaceuticals,

Inc.*

............................................

3,050

2,935,595‌

Revvity

Inc

...............................................................

25,919

2,721,495‌

Royalty

Pharma

PLC,

Class

A

...............................................

148,455

4,508,578‌

Sarepta

Therapeutics

Inc*

...................................................

90,523

11,719,108‌

Shockwave

Medical,

Inc.*

...................................................

14,945

4,866,540‌

Stryker

Corp.

.............................................................

5,089

1,821,200‌

Syndax

Pharmaceuticals,

Inc.*

...............................................

25,337

603,021‌

Tenet

Healthcare

Corp.*

....................................................

4,713

495,383‌

Thermo

Fisher

Scientific,

Inc.

................................................

8,271

4,807,188‌

Ultragenyx

Pharmaceutical

Inc*

..............................................

30,753

1,435,858‌

UnitedHealth

Group,

Inc.

....................................................

1,900

939,930‌

Veeva

Systems,

Inc.,

Class

A*

...............................................

1,936

448,552‌

Zimmer

Biomet

Holdings

Inc

.................................................

25,796

3,404,556‌

124,240,066‌

Industrials

–

1.9%

3M

Co

..................................................................

24,530

2,601,897‌

Veralto

Corp.

.............................................................

388

34,400‌

2,636,297‌

Simplify

Health

Care

ETF

Schedule

of

Investments

(Continued)

March

31,

2024

(Unaudited)

2

††

The

percentage

shown

for

each

investment

category

is

the

total

value

of

investments

in

that

category

as

a

percentage

of

the

net

assets

of

the

Fund.

The

table

depicts

the

Fund's

investments

but

may

not

represent

the

Fund's

market

exposure

to

certain

derivatives,

if

any,

which

are

included

in

Other

Assets

in

Excess

of

Liabilities.

Shares

Value

Common

Stocks

(continued)

Materials

–

4.9%

PureCycle

Technologies,

Inc.*

...............................................

1,064,440

$

6,620,817‌

Total

Common

Stocks

(Cost

$120,797,281)

.........................................

133,497,180‌

Money

Market

Funds

–

1.9%

Fidelity

Investments

Money

Market

Treasury

Only

Portfolio

-

Class

I,

5.20%(a)

(Cost

$2,590,732)

.......................................................

2,590,732

2,590,732‌

Total

Investments

–

100.0%

(Cost

$123,388,013)

...........................................................

$

136,087,912‌

Other

Assets

in

Excess

of

Liabilities

–

0.0%†

..........................................

21,596‌

Net

Assets

–

100.0%

............................................................

$

136,109,508‌

*

Non

Income

Producing

†

Less

than

0.05%

(a)

Rate

shown

reflects

the

7-day

yield

as

of

March

31,

2024.

Summary

of

Investment

Type††

Industry

%

of

Net

Assets

Common

Stocks

.................................................................................

98.1‌%

Money

Market

Funds

.............................................................................

1.9‌%

Total

Investments

................................................................................

100.0‌%

Other

Assets

in

Excess

of

Liabilities

..................................................................

0.0‌%†

Net

Assets

.....................................................................................

100.0‌%